Therapeutic and diagnostic methods for cancer

US11300570B2 · kind B2 · utility

Assignees

• Genentech, Inc. · US
• Foundation Medicine, Inc. · US

Inventors

• David Fabrizio · Hamilton, US
• Garrett Michael Frampton · Somerville, US
• Priti HEGDE · San Mateo, US
• Marcin KOWANETZ · San Francisco, US
• David Shames · South San Francisco, US
• Philip James Stephens · Lexington, US
• James Xin Sun · Cambridge, US
• Roman Yelensky · Newton, US
• Wei Zou · Ottawa, CA

Key dates

• Filing date: Apr 1, 2019
• Grant date: Apr 12, 2022
• Expiry date: Jul 15, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A90/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which…